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Abstract
Background:  Hyperglycemia or hyperinsulinemia contributes to poorer endometrial cancer
survival. It was shown that P-LAP/IRAP translocates to the plasma membrane in response to insulin
stimulation. Recently, we demonstrated that P-LAP/IRAP is associated with a poor prognosis in
endometrial adenocarcinoma patients. The aim of this study was to examine whether the malignant
potential of endometrial cancer enhanced by P-LAP/IRAP is due to increased glucose uptake via the
P-LAP/IRAP-mediated activation of insulin signaling.
Methods: We transfected P-LAP/IRAP cDNA into A-MEC cells (endometrial adenocarcinoma cell
line), and A-MEC-LAP cells expressed a remarkably high level of GLUT4 proteins.
Results: 3H-2-deoxyglucose uptake which responds to insulin in A-MEC-LAP cells was significantly
higher than that of A-MEC-pc cells. A-MEC-LAP cells exhibited a significant growth-stimulatory
effect compared to A-MEC-pc cells. A-MEC-LAP cells expressed a remarkably high level of p85PI3K
protein compared to A-MEC-pc cells, and showed a higher degree of AKT phosphorylation by
insulin stimulation.
Conclusion:  In summary, P-LAP/IRAP was involved in the increasing malignant potential of
endometrial cancer mediated by insulin. P-LAP/IRAP was suggested to be a potential new target of
molecular-targeted therapy for endometrial cancer.
Background
Endometrial carcinoma is the most common gynecologi-
cal malignancy in the United States. Recently, the inci-
dence of this disease has been increasing in Japan. Several
personal and lifestyle-related characteristics, such as age,
obesity, diabetes, and estrogen therapy, have been identi-
fied as risk factors for developing endometrial cancer [1].
A recent study showed that diabetes is associated with
reduced survival after endometrial cancer, independent of
tumor stage and grade [2]. This finding suggested the pos-
sibility of a diabetes-related condition, such as hyperglyc-
emia or hyperinsulinemia, contributing to reduced
survival in endometrial cancer patients. Furthermore, an
in vitro study showed that endometrial cancer cells have
high-affinity binding sites for insulin and proliferate in
response to insulin exposure [3]. Several studies have
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shown that insulin signal transduction proteins, in partic-
ular the insulin receptor (IR) and IRS-1, may also contrib-
ute to the development of various tumors [4,5].
Placental leucine aminopeptidase (P-LAP) is a cell surface
aminopeptidase, and is a synonym for oxytocinase [6]. P-
LAP is also referred to as insulin-regulated membrane
aminopeptidase (IRAP), associated with the glucose trans-
porter 4 (GLUT4) containing vesicle [7-9]. It was shown
that P-LAP/IRAP translocates to the plasma membrane in
response to insulin stimulation. Recently, we demon-
strated that P-LAP/IRAP is present in both human
endometrial adenocarcinoma tissues and cells, and that it
acts as a regulator of carcinoma cell growth [10]. Further-
more, we demonstrated that P-LAP/IRAP is associated
with a poor prognosis in human endometrial adenocarci-
noma patients [11]. The aim of this study was to examine
whether the proliferation of endometrial cancer enhanced
by P-LAP/IRAP is due to increased glucose uptake via the
P-LAP/IRAP-mediated activation of insulin signaling.
Methods
Tissues
Tissue specimens were obtained from patients who were
surgically treated at Nagoya University Hospital. All tissue
samples were fixed in 10% formalin, embedded in paraf-
fin, and routinely stained with hematoxylin and eosin for
histological examination. Endometrial adenocarcinomas
were graded according to the criteria of the World Health
Organization and classified as grade 1 (well-differenti-
ated), grade 2 (moderately- differentiated), or grade 3
(poorly-differentiated). The relevant institutional review
boards approved the study and informed consent from
which all patients signed.
Cell lines and culture conditions
We used 3 human endometrial endometrioid adenocarci-
noma cell lines (A-MEC, HEC1A, and Ishikawa). A-MEC
was a kind gift from Aichi Medical University, Ishikawa
from Dr. M. Nishida (Kasumigaura Hospital, Ibaragi,
Japan), and HEC1A from Professor H. Kuramoto (Kita-
zato University, Kanagawa, Japan). Cells were maintained
in RPMI 1640 medium (Sigma Chemical Co., St. Louis,
MO) supplemented with 10% fetal calf serum (FCS) and
penicillin-streptomycin. These cells were incubated at 37
C in a humidified atmosphere of 5% CO2.
Immunohistochemistry
Immunohistochemical staining was performed using the
avidin-biotin immunoperoxidase technique (Histofine
SAB-PO kit, Nichirei, Tokyo, Japan). Sections were cut at
a thickness of 4 μm, and immunostained by the streptavi-
din/biotin/peroxidase method. Deparaffinized sections in
0.01 M citrate buffer were treated three times for 5 min
each at 90 C and 750 W using an H2500 microwave oven.
Sections were incubated in 0.3 % hydrogen peroxide for
20 min and then further incubated with 10 % normal goat
serum for 10 min to block the endogenous peroxidase
activity and non-specific immunoglobulin binding,
respectively. Rabbit polyclonal antibody (sc-710, Santa
Cruz Biotechnology, Inc., Santa Cruz, CA) at a 1:100 dilu-
tion was used for insulin receptor (IR) a, rabbit polyclonal
antibody (Upstate, Inc., Lake Placid, NY) at 1:200 dilution
was used for insulin receptor substrate-1 (IRS-1), rabbit
polyclonal antibody (Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA) at a 1:50 dilution was used for GLUT4,
and rabbit polyclonal antibody at 1: 100 was used for P-
LAP/IRAP. They were added to the tissue sections and
incubated for 1 h in a moist chamber at room tempera-
ture. Binding of the antibodies was followed with bioti-
nylated goat anti-rabbit IgG and horse-radish peroxidase-
conjugated streptavidin (Histofine SAB-PO, Nichirei).
Chromogenic development was performed by immersion
of the sections in 3-amino-9-ethylcarbazole (AEC,
Nichirei). The slides were counterstained with Mayer's
hematoxylin.
Plasmid construction and transfection
The eukariotic expression vector pcDNA3.1(-) (Invitrogen
Japan K.K., Tokyo, Japan) was used to drive the expression
of inserted P-LAP/IRAP cDNA. Transfections were carried
out using Lipofectamine according to the manufacturer's
instructions (Invitrogen Japan K.K., Tokyo, Japan). A-
MEC cells were transfected with pcDNA3.1(-) (A-MEC-pc)
or pcDNA3.1(-) inserted with P-LAP/IRAP cDNA (A-MEC-
LAP). Stable transfectants were selected by growth in
medium supplemented with 400 mg/ml of G418 (Sigma
Chemical Co., St. Louis, MO). Several hundred clones
resistant to G418 were obtained and polyclonal cells from
these transfectants were used in the following experiments
to eliminate any effects that could be attributed to clonal
variation.
Western blotting
Cell lysates were electrophoresed on 7.5% sodium
dodecyl sulfate polyacrylamide gel under reducing condi-
tions. After electrophoresis, the proteins were transferred
electrophoretically to an Immobilon membrane (Milli-
pore, Bedford, MA, USA). After blocking, the membrane
was incubated for 1 h with rabbit polyclonal antibody
against human P-LAP/IRAP, GLUT4, insulin receptor, IRS-
1, p-Ser307-IRS1 (Upstate Biotechnology, Lake Placid,
NY), p-Tyr1158-IR(Abcam, Cambrige, UK), and mouse
monoclonal antibody for phospho-AKT (587F11, Cell
Signaling Technology, Inc.) and p85 PI-3 kinase (sc-1637,
Santa Cruz Biotechnology, Inc., Santa Cruz, CA) The
membrane was washed with TBS-T for 15 min three times,
and then incubated with peroxidase-conjugated goat anti-
rabbit IgG for 1 h. After washing with TBS-T, the mem-BMC Cancer 2007, 7:15 http://www.biomedcentral.com/1471-2407/7/15
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brane was subjected to ECL-Western blotting detecting
reagent (Amersham Biosciences K.K., Tokyo, Japan).
Cellular glucose uptake in P-LAP/IRAP transfection cells
A-MEC-pc and A-MEC-LAP cells were cultured in 12-well
plates. Twenty-four h after plating, the cells were serum-
starved for 2 h, then incubated in either the presence or
absence of 10 nM insulin for 20 min, followed by the
addition of 2-deoxy-D-2,6-3H-glucose to a final concen-
tration of 1 μCi/ml. Insulin was purchased from Sigma
(Japan).
Cell growth analysis
To evaluate the effect of insulin on cell proliferation, cells
were seeded in triplicate in 96-well plates at a density of
5000 cells in a volume of 200 ml. Twenty-four h after plat-
ing, insulin was added to the culture medium at concen-
trations ranging from 10-8 to 10-7 M in the presence 5%
FCS. Cell viability after 48 h was assayed using a modified
tetrazolium salt 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphe-
nyltetrazolium bromide assay with the Cell Titer 96 Aque-
ous One Solution Cell Proliferation Assay kit (Promega
Corp., Tokyo, Japan) according to the manufacturer's
instructions. Absorbance was measured at 490 nm by a
microplate reader (Multiskan Bichromatic, Labsystems,
Helsinki, Finland).
Statistical analysis
Statistical comparisons among groups were performed
using Student's t-test and ANOVA with Bonferroni correc-
tions. Differences between groups were considered signif-
icant at p < 0.05.
Results
Expressions of P-LAP/IRAP, GLUT4, IR, and IRS-1 in 
endometrial carcinoma tissues and cell lines
We first examined the expressions of P-LAP/IRAP, GLUT4,
IR, and IRS-1 in human endometrial carcinoma tissues by
immuohistochemistry. In 26 of 35 endometrial adenocar-
cinomas, tumor cells were P-LAP/IRAP-positive. In all
positive tumor cells, P-LAP/IRAP staining was intense and
localized at the periphery of the cytoplasm, close to the
cell membrane (Fig. 1A). We showed a significant ten-
dency of increased immunoreactivity with grade advance-
ment in the previous report [10]. In 27 of 35 cases, tumor
cells were GLUT4-positive. GLUT4 was stained in both the
cell membrane and cytoplasm (Fig. 1B). The intensity of
immunohistochemical staining was scored and plotted in
Fig. 1F, showing the tendency of increased immunoreac-
tivity with grade advancement. In 26 of 35 endometrial
adenocarcinomas, tumor cells were IR-positive. IR was
stained in the cell membrane (Fig. 1C). In 23 of 35 cases,
tumor cells were IRS-1 positive. IRS-1 was stained in both
the cell membrane and periphery of the cytoplasm (Fig.
1D). Neither the IR nor the IRS-1 staining levels showed
any correlation with tumor grade advancement (data not
shown). A-MEC, HEC-1A, and Ishikawa cells were all pos-
itive for P-LAP/IRAP and GLUT-4 on Western blotting. A-
MEC cells showed the lowest expressions of P-LAP/IRAP
and GLUT-4 among these cell lines. Ishikawa cells showed
the highest expressions of P-LAP/IRAP and GLUT-4
among these cell lines (Fig. 2A). To investigate the effect
of P-LAP/IRAP transfection on GLUT4, IR, and IRS-1
expressions in carcinoma cells, we overexpressed P-LAP/
IRAP in A-MEC cells (A-MEC-LAP). While both parental
A-MEC and expressed few GLUT4 proteins, A-MEC-LAP
cells expressed a remarkably high level of GLUT4 proteins
(Fig. 2B). Both IR and IRS-1 expressions in A-MEC-LAP
cells were at similar levels compared with A-MEC and A-
MEC-pc cells (Fig. 2B).
Involvement of P-LAP/IRAP in glucose uptake in 
endometrial carcinoma cells
To determine whether the aberrant expression of P-LAP/
IRAP influenced glucose uptake, insulin-stimulated rates
of cellular glucose uptake were assessed in A-MEC-pc and
A-MEC-LAP cells. As shown in Fig. 3, 3H-2-deoxyglucose
uptake which responds to insulin in A-MEC-LAP cells was
significantly higher than that of A-MEC-pc cells.
Involvement of P-LAP/IRAP in insulin-induced cell growth
We next investigated the effects of insulin on cell prolifer-
ation in A-MEC, A-MEC-pc, and A-MEC-LAP cells. As
shown in Fig. 4, the addition of insulin increased cell
numbers in a dose-dependent manner in A-MEC cells. In
particular, A-MEC-LAP cells exhibited a growth-stimula-
tory effect of insulin and the addition of 10-7 M of insulin
led to a significant effect compared to A-MEC and A-MEC-
pc cells.
The effect of P-LAP/IRAP transfection on insulin induced 
activation of the PI3K/AKT pathway in A-MEC cells
We next investigated whether the PI3K/AKT pathway was
activated by insulin in A-MEC, A-MEC-pc, and A-MEC-
LAP cells. A-MEC-LAP cells expressed a remarkably high
level of p85PI3K protein compared with A-MEC or A-
MEC-pc cells. Insulin stimulation enhanced AKT phos-
phorylation in all A-MEC, A-MEC-pc, and A-MEC-LAP
cells, among which A-MEC-LAP cells showed the highest
degree of AKT phosphorylation. Insulin stimulated IR and
IRS1 phosphorylation were observed in all A-MEC, A-
MEC-pc, and A-MEC-LAP cells to the same degree (Fig. 5).
Blockade of the PI3K/Akt pathway inhibited the effect of 
insulin on A-MEC-LAP cell
The activation of AKT after treatment with insulin
involves multiple pathways. To determine the functional
role of PI3K/AKT activation in the insulin-induced cell
proliferation of A-MEC-LAP cells, A-MEC-LAP cells were
pre-treated with the PI3K inhibitor, wortmannin, 1 hBMC Cancer 2007, 7:15 http://www.biomedcentral.com/1471-2407/7/15
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before of insulin treatment. As shown in Fig. 6, the pre-
treatment of A-MEC-LAP cells with wortmannin, signifi-
cantly inhibited insulin-induced cell proliferation (Fig.
6A) and activation of AKT (Fig. 6B)(* p < 0.05).
Discussion
Tumorigenesis is associated with enhanced cellular glu-
cose uptake and increased metabolism. Indeed, both
GLUT1 and GLUT4 are aberrantly expressed in many
tumors; for example, overexpression of GLUT1 is found in
breast, thyroid, gastric, and liver cancer [10-13]. GLUT4 is
expressed in human astrocytic tumors, a subset of lung
cancers, gastric cancer, and rhabdomyosarcoma [14-17].
Furthermore, a recent study showed that the tumor sup-
pressor p53 down regulates GLUT1 and GLUT4 gene
expression [18]. In previous studies, we demonstrated
that P-LAP/IRAP was a poor prognostic factor of endome-
trial cancer, and that P-LAP/IRAP was involved in prolifer-
ation, anticancer agent resistance, and anti-apoptosis by a
P-LAP/IRAP gene transfer experiment [11,12,19]. In this
study, we showed the tendency of an increased GLUT4
immunoreactivity with the advancement of the tumor
grade, and this tendency was similar to the results of P-
LAP/IRAP. Diabetes and hyperglycemia are poor prognos-
tic factors of endometrial cancer, and in vitro insulin
responsiveness and enhanced proliferation of endome-
trial cancer cells have also been reported
[1,2,13,14,20,21]. P-LAP/IRAP resides in GLUT4 vesicles,
and is known to migrate to the cell membrane to facilitate
glucose uptake into cells in response to insulin stimula-
tion. In this study, we first demonstrated that P-LAP/IRAP
gene transfer increased GLUT4 expression in endometrial
cancer cell lines, with resulting increases in glucose uptake
into cells and the cell proliferation capacity in response to
insulin. Also, increased PI3K-AKT signal expression, a rep-
resentative one in insulin signaling, was noted in the P-
LAP/IRAP gene-transferred cells. The above results suggest
the involvement of P-LAP/IRAP expression in insulin-
induced carcinogenesis and a higher degree of malignancy
of endometrial cancer cells. Recently, there have been sev-
eral reports concerning activated AKT signal involvement
in anticancer agent resistance [22-24]. We also reported
the involvement of P-LAP/IRAP in anticancer agent resist-
ance and anti-apoptosis. These results suggest that P-LAP/
Immunochemical localizations of P-LAP/IRAP, GLUT4, IR, and IRS-1 in human endometrioid adenocarcinoma tissues (Magnifi- cation, × 200) Figure 1
Immunochemical localizations of P-LAP/IRAP, GLUT4, IR, and IRS-1 in human endometrioid adenocarcinoma tissues (Magnifi-
cation, × 200). A: P-LAP/IRAP in a grade 2 endometrioid adenocarcinoma. B: GLUT4. C: IR. D: IRS 1. Immunoreactivites of P-
LAP/IRAP, GLUT4, IR, and IRS-1 were positive in carcinoma cells. E: Negative control (no primary antibody) in normal 
endometrial tissue.BMC Cancer 2007, 7:15 http://www.biomedcentral.com/1471-2407/7/15
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Effect of insulin on cell proliferation in A-MEC, A-MEC-pc,  and A-MEC-LAP cells Figure 4
Effect of insulin on cell proliferation in A-MEC, A-MEC-pc, 
and A-MEC-LAP cells. Treatment with insulin increased cell 
proliferation at concentrations of 10-8 and 10-7 M. A-MEC-
LAP cells exhibited a growth-stimulatory effect via insulin, 
and the addition of 10-7 M of insulin led to a significant effect 
compared with A-MEC and A-MEC-pc cells (p < 0.05).
A. Expressions of P-LAP/IRAP, GLUT4, IR, and IRS-1 in three endometrial carcinoma cell lines Figure 2
A. Expressions of P-LAP/IRAP, GLUT4, IR, and IRS-1 in three endometrial carcinoma cell lines. Lanes are as follows: lane 1, A-
MEC cells; lane 2, HEC-1A cells; lane 3, Ishikawa cells. B. The effect of P-LAP/IRAP transfection on GLUT4, IR, and IRS-1 
expressions in A-MEC cells. Lanes are as follows: lane 1, A-MEC cells; lane 2, A-MEC-pc cells; lane 3, A-MEC-LAP cells.
Cellular glucose uptake rates in A-MEC-pc and A-MEC-LAP  cells Figure 3
Cellular glucose uptake rates in A-MEC-pc and A-MEC-LAP 
cells. 3H-2-deoxyglucose uptake was measured as either 
basal or insulin-stimulated (10 nM insulin) for 30 min. Insulin-
stimulated compared with basal rates in A-MEC-pc and A-
MEC-LAP cells are shown. Data are expressed as the mean ± 
SEM of three separate experiments.BMC Cancer 2007, 7:15 http://www.biomedcentral.com/1471-2407/7/15
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IRAP may also be involved in anticancer agent resistance
via the activation of insulin signaling. We had postulated
the involvement of enzyme activity in many cases of P-
LAP/IRAP-induced increased proliferation and the anti-
cancer agent resistance of endometrial cancer cells, and, in
this study, we demonstrated the possibility that an
increased glucose uptake into the cells by insulin also
induces cell proliferation in endometrial cancer cells. Fur-
ther studies on the mechanism of increased GLUT4
expression by P-LAP/IRAP gene transfer are needed in the
future. In this regard, the involvement of hormonal treat-
ment (e.g., estrogen and progesterone) and p53 in the reg-
ulation of GLUT4 expression has been reported [18,25],
and their implications in P-LAP/IRAP expression must
therefore be investigated.
In summary, P-LAP/IRAP was involved in the progression
of endometrial cancer mediated by insulin signaling. P-
LAP/IRAP was suggested to be a potential new target of
molecular-targeted therapy for endometrial cancer.
Conclusion
This work demonstrated that P-LAP/IRAP is involved in
the increasing malignant potential of endometrial cancer
mediated by insulin and to be a potential new target of
molecular-targeted therapy for endometrial cancer.
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